AI Article Synopsis
- A study involved 106 patients with advanced ovarian cancer who underwent optimal surgery followed by 9 cycles of CHAP chemotherapy, with clinical responses confirmed later.
- Out of these patients, 65% showed a response to treatment, with about 51% achieving complete remission; however, some faced complications leading to no further treatment.
- The 5-year survival rate was noted at 32.5%, and factors like age, initial cancer stage, residual disease, and grading significantly impacted prognosis, leading to the proposal of a new classification system to enhance treatment outcomes.
Article Abstract
One hundred and six patients with stage Ic to IV ovarian carcinoma were treated by a protocol consisting of optimal debulking surgery followed by 9 cycles of CHAP chemotherapy. Clinical response was confirmed by a second-look procedure. Sixty-nine patients (65%) responded with 54 histological complete remissions (50.8%). Nineteen patients did not receive any complementary treatment due to a negative reaction, or prolonged neutropenia. Seven patients received maintenance chemotherapy, 10 an abdominal radiotherapy, 22 intraperitoneal chemotherapy and 11 autologous bone marrow transplantation. The 5-year survival rate was 32.5% and disease-free survival rate was 39.7%. Prognostic-factor analysis showed that age, initial staging, residual disease and cytological grading were significant. The authors propose a classification based on the risk of relapse, and different therapeutic indications for improving response rate and patient survival.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!